Skip to main content

Advertisement

Table 4 Results of traditional meta-analysis and meta-regression analyses of proportion of INR measurements in range

From: Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression

   Proportion of INR measurements in range
Study-level factors No. (%) Unadjusted pooled mean upon subgroup analysis, % (95% CI) Adjusted difference, % (95% CI) p-v alue
All study groups 24 (100) 56 (53 to 59) NA NA
Study setting     
  AC Clinic 5 (20.8) 60 (58 to 62) 6.9 (−0.02 to 15.2) 0.13
  RCT 5 (20.8) 61 (54 to 68) 5.6 (−0.06 to 17.0) 0.36
  Community 14 (58.3) 54 (50 to 57) Referent  
Study year     
  1990-2000 6 (25.0) 54 (46 to 64) 3.3 (−25.3 to 31.9) 0.82
  2001-2007 13 (54.2) 56 (54 to 59) −2.8 (−14.8 to 9.2) 0.65
  2008-2013 5 (20.8) 56 (51 to 62) Referent  
Self-management     
  No 22 (91.7) 55 (43 to 57) −9.3 (−32.4 to 13.8) 0.45
  Yes 2 (8.3) 69 (67 to 72) Referent  
Geographic region     
  Europe/UK 13 (54.2) 57 (54 to 60) −1.7 (−10.7 to 7.3) 0.71
  Asia 2 (8.3) 56 (48 to 66) −8.8 (−26.4 to 8.8) 0.32
  Other 0 (0) NA NA NA
  Multinational 0 (0) NA NA NA
  North America 9 (37.5) 54 (48 to 62) Referent  
VKA experience     
  NR/Mixed 5 (20.8) 51 (41 to 63) −5.7 (−34.7 to 23.3) 0.83
  No 3 (12.5) 63 (55 to 73) 7.9 (−15.2 to 31.0) 0.65
  Yes 17 (70.8) 56 (54 to 59) Referent  
Duration of VKA treatment     
  ≥1 year 17 (70.8) 57 (54 to 60) 9.1 (−0.5 to 18.7) 0.09
  <1 year 7 (29.2) 53 (44 to 65) Referent  
  1. AC = anticoagulation; CI = confidence interval; NA = not applicable; No. = number of study arms; NR = not reported; RCT = randomized controlled trial; UK = United Kingdom; VKA = Vitamin K Antagonists.